Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology.
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Biostage's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BSTG's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BSTG underperformed the US Biotechs industry which returned 22% over the past year.
Return vs Market: BSTG matched the US Market which returned 3.7% over the past year.
Price Volatility Vs. Market
How volatile is Biostage's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biostage undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BSTG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BSTG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BSTG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BSTG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BSTG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BSTG is overvalued based on its PB Ratio (38.3x) compared to the US Biotechs industry average (3.8x).
How is Biostage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biostage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Biostage's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Biostage's filings and announcements here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Biostage performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSTG is currently unprofitable.
Growing Profit Margin: BSTG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BSTG is unprofitable, but has reduced losses over the past 5 years at a rate of 9.1% per year.
Accelerating Growth: Unable to compare BSTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BSTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.3%).
Return on Equity
High ROE: BSTG has a negative Return on Equity (-1304.5%), as it is currently unprofitable.
How is Biostage's financial position?
Financial Position Analysis
Short Term Liabilities: BSTG's short term assets ($1.2M) exceed its short term liabilities ($1.0M).
Long Term Liabilities: BSTG's short term assets ($1.2M) exceed its long term liabilities ($61.0K).
Debt to Equity History and Analysis
Debt Level: BSTG is debt free.
Reducing Debt: BSTG had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BSTG has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BSTG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Biostage's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BSTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BSTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSTG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSTG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSTG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Biostage has no CEO, or we have no data on them.
|VP of Finance & Acting Principal Financial and Accounting Officer||0.17yr||US$249.31k||0.27% $68.8k|
|Chief Scientific Officer||2.83yrs||US$322.15k||no data|
|Vice President of Business Development & Operations||0.17yr||no data||no data|
Experienced Management: BSTG's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Co-Chairman of Scientific Advisory Board||4.5yrs||no data||no data|
|Co-Chairman of Scientific Advisory Board||no data||no data||no data|
|Independent Director||1.5yrs||US$45.00k||0.29% $72.3k|
|Independent Director||2.17yrs||US$45.00k||no data|
|Member of Scientific Advisory Board||2.25yrs||no data||no data|
|Chairman of the Board||2.25yrs||US$62.91k||0.41% $104.0k|
|Member of Scientific Advisory Board||2.33yrs||no data||no data|
|Independent Director||2yrs||US$57.16k||no data|
|Independent Director||1.5yrs||US$48.01k||no data|
Experienced Board: BSTG's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.1%.
Biostage, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biostage, Inc.
- Ticker: BSTG
- Exchange: OTCPK
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$25.088m
- Shares outstanding: 8.68m
- Website: https://biostage.com
Number of Employees
- Biostage, Inc.
- 84 October Hill Road
- Suite 11
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BSTG||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Apr 2013|
|H3AA||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Apr 2013|
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company’s Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient’s own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/24 05:32|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.